entertainment -WSS

entertainment

author：leisure time 2025-10-02 18:48:45 - browse：81955

LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy in a trial, but investors found the results less impressive than anticipated, sending company shares down in early trading.

Based on an interim analysis of a Phase 3 trial, the company said that the drug, datopotamab deruxtecan, led to improvement in progression-free survival in patients non-small cell lung cancer, a primary endpoint of the study. There was also a positive early trend on overall survival, with Susan Galbraith, AstraZeneca’s oncology leader, describing the results as “compelling evidence for the potential role” that the drug could play for patients.

But investors had been hoping for a clearer signal of benefit. Analysts noted that despite the success in progression-free survival, it was not described as a “clinically meaningful” improvement, which, as J.P. Morgan analysts wrote, “we believe the market would have liked to have seen.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Prosthetic arm enables patients to feel the objects they grip

explore

WSS

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

Report: NIH

Study: Why relieving medical debt did not improve financial outcomes

Do more moles mean more problems? Not so, says new study

Insmed lung disease drug hits target in key Phase 3 trial

How faith leaders like me can help address America's obesity epidemic

focus

entertainment

entertainment

Medicare proposal to cover medical devices draws a mixed reaction

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Trump demands the U.S. pay no more for drugs than other countries … again

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

New air purifier tech could be key to improving indoor air quality

Lab trade group sues FDA to halt regulation of lab

Activists slam private health insurers over coverage restrictions

5 takeaways from STAT's examination of Zynex Medical

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Readers discuss the intersection of pregnancy and addiction

explore

Biohaven protein

Latest bird flu infection made farmworker sicker than earlier cases

First Opinion Podcast: What happens when kids become caregivers?

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

NIH tests clinical research in primary care with $30 million program

What will save rural psychiatry services? Higher Medicaid payments

Wikipedia

explore

focus

focus